p53, bcl-2 and Retinoblastoma Proteins as Long-Term Prognostic Markers in Localized Carcinoma of the Prostate-Reference-Cited by-同舟云学术

p53, bcl-2 and Retinoblastoma Proteins as Long-Term Prognostic Markers in Localized Carcinoma of the Prostate

Published:1997-07 Issue:1 Volume:158 Page:131-137
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Theodorescu Dan¹,Broder Stanford R.¹,Boyd James C.¹,Mills Stacey E.¹,Frierson Henry F. Jr¹

Affiliation:

1. From the Departments of Urology, Molecular Physiology and Biological Physics, and Pathology, University of Virginia Health Sciences Center, Charlottesville, Virginia.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference40 articles.

1. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection.;Epstein;Sem. Oncol.,1994

2. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).;Epstein;J. Urol.,1994

3. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.;Ohori;J. Urol.,1994

4. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.;Catalona;J.A.M.A.,1993

5. Newer applications of serum prostate-specific antigen in the management of prostate cancer.;Takayama;Sem. Oncol.,1994

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of Expression of P53 in Prostatic Lesions;Journal of Pharmaceutical Research International;2021-04-09

2. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives;Critical Reviews in Oncology/Hematology;2021-01

3. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer);BMJ Open;2020-01

4. Re: Genomic Correlates of Clinical Outcome in Advanced Prostate Cancer;Journal of Urology;2019-12

5. The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy;Advances in Anatomic Pathology;2019-09-09